UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  FORM 10-QA/SB

[x]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934

      For the quarter ended June 30, 2005

                                          or

[    ]  Transition  Report  Pursuant  to Section  13 or 15(d) of the  Securities
     Exchange Act of 1934

       For the transition period from ___________ to ________________

       Commission File Number:   0-10379


                            INTERFERON SCIENCES, INC.
             (Exact Name of Registrant as Specified in its Charter)


Delaware                                                           22-2313648
(State or other jurisdiction of                              (I.R.S. Employer
incorporation or organization)                            Identification No.)


1812 Front Street, Scotch Plains, New Jersey                           07076
(Address of principal executive offices)                           (Zip code)


(908) 663-2150
(Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period) that the registrant was
required to file such reports and (2) has been subject to such filing
requirements for the past 90 days.

                                 Yes [X] No [ ]


Number of shares outstanding of each of issuer's classes of common stock as of
August 1, 2005.

                   Common Stock               37,339,286 shares



<PAGE>




                    INTERFERON SCIENCES, INC. AND SUBSIDIARY

                           PART II. OTHER INFORMATION



Item 6.    Exhibits and Reports on Form 8-K

            Exhibits

           32.1     Certification pursuant to Section 906 of the
                    Sarbanes-Oxley Act of 2002 from the Company's
                    Chief Executive Officer

           32.2     Certification pursuant to Section 906 of the
                    Sarbanes-Oxley Act of 2002 from the Company's
                    Chief Financial Officer












                            INTERFERON SCIENCES, INC.

                                  June 30, 2005




                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.



                                               INTERFERON SCIENCES, INC.




DATE:  September 19, 2005                    By:  /s/ Lawrence M. Gordon
                                                      Lawrence M. Gordon
                                                      Chief Executive Officer




DATE:  September 19, 2005                    By:  /s/ Donald W. Anderson
                                                      Donald W. Anderson
                                                      Controller


<PAGE>


Exhibit 32.1



                            CERTIFICATION PURSUANT TO
                               SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Interferon Sciences, Inc. (the
"Company") on Form 10-Q for the fiscal quarter ended June 30, 2005 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Lawrence M. Gordon, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

          (1) The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

          (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.


Date: August 14, 2005


                                                /s/ Lawrence M. Gordon
                                               -----------------------
                                                Lawrence M. Gordon
                                                Chief Executive Officer












EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                               SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Interferon Sciences, Inc. (the
"Company") on Form 10-Q for the fiscal quarter ended June 30, 2005 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Donald W. Anderson, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

          (1) The Report fully complies with the requirements of section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and

          (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.


Date: August 14, 2005


                                                /s/ Donald W. Anderson
                                               -----------------------
                                                Donald W. Anderson
                                                Chief Financial Officer